Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
COM-701 by Compugen for Invasive Ductal Carcinoma: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Invasive Ductal Carcinoma. According to GlobalData, Phase...
COM-701 by Compugen for Metastatic Breast Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase...
COM-701 by Compugen for Oropharyngeal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Oral Cavity (Mouth) Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
COM-701 by Compugen for Nasopharyngeal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Hypopharyngeal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Endometrial Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Peritoneal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Laryngeal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Metastatic Colorectal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
COM-701 by Compugen for Fallopian Tube Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
COM-701 by Compugen for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...
COM-701 by Compugen for Non-Small Cell Lung Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
COM-701 by Compugen for Colorectal Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
COM-701 by Compugen for Ovarian Cancer: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
COM-701 by Compugen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
COM-701 by Compugen for Solid Tumor: Likelihood of Approval
COM-701 is under clinical development by Compugen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Compugen's COM-701?
COM-701 is a monoclonal antibody commercialized by Compugen, with a leading Phase II program in Ovarian Cancer;Endometrial Cancer;Fallopian Tube Cancer....